CN120129539A - 放射性核素组合物及其用于检测肿瘤细胞的方法 - Google Patents

放射性核素组合物及其用于检测肿瘤细胞的方法 Download PDF

Info

Publication number
CN120129539A
CN120129539A CN202380075881.0A CN202380075881A CN120129539A CN 120129539 A CN120129539 A CN 120129539A CN 202380075881 A CN202380075881 A CN 202380075881A CN 120129539 A CN120129539 A CN 120129539A
Authority
CN
China
Prior art keywords
alkyl
independently
alkylaryl
alkylheteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380075881.0A
Other languages
English (en)
Chinese (zh)
Inventor
雅各布·霍顿
维尔玛·贾利诺亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Publication of CN120129539A publication Critical patent/CN120129539A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0404—Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406—Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1268—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules host-guest, closed hollow molecules, inclusion complexes, e.g. with cyclodextrins, clathrates, cavitates, fullerenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F17/00—Metallocenes
    • C07F17/02—Metallocenes of metals of Groups 8, 9 or 10 of the Periodic Table
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202380075881.0A 2022-09-09 2023-09-08 放射性核素组合物及其用于检测肿瘤细胞的方法 Pending CN120129539A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263375159P 2022-09-09 2022-09-09
US63/375,159 2022-09-09
US202363481517P 2023-01-25 2023-01-25
US63/481,517 2023-01-25
PCT/US2023/073725 WO2024054972A2 (fr) 2022-09-09 2023-09-08 Composition radionucléidique et procédé d'utilisation associée pour la détection de cellules tumorales

Publications (1)

Publication Number Publication Date
CN120129539A true CN120129539A (zh) 2025-06-10

Family

ID=90191967

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380075881.0A Pending CN120129539A (zh) 2022-09-09 2023-09-08 放射性核素组合物及其用于检测肿瘤细胞的方法

Country Status (8)

Country Link
EP (1) EP4583928A2 (fr)
JP (1) JP2025530298A (fr)
KR (1) KR20250065366A (fr)
CN (1) CN120129539A (fr)
AU (1) AU2023338487A1 (fr)
CA (1) CA3266257A1 (fr)
IL (1) IL319424A (fr)
WO (1) WO2024054972A2 (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160331852A1 (en) * 2015-05-11 2016-11-17 Memorial Sloan Kettering Cancer Center Radioligands for pretargeted pet imaging and methods of their therapeutic use
WO2019195890A1 (fr) * 2018-04-11 2019-10-17 Clarity Pharmaceuticals Pty Ltd Formulations et kits pour radiothérapie et imagerie diagnostique

Also Published As

Publication number Publication date
WO2024054972A3 (fr) 2024-04-18
JP2025530298A (ja) 2025-09-11
WO2024054972A2 (fr) 2024-03-14
IL319424A (en) 2025-05-01
CA3266257A1 (fr) 2024-03-14
AU2023338487A1 (en) 2025-03-20
EP4583928A2 (fr) 2025-07-16
KR20250065366A (ko) 2025-05-12

Similar Documents

Publication Publication Date Title
CN111285918B (zh) 用于psma靶向的成像和放射疗法的金属/放射性金属标记的psma抑制物
ES2844586T3 (es) Inhibidores del antígeno prostático específico de membrana (PSMA) etiquetados con 18F y su uso como agentes de obtención de imágenes para el cáncer de próstata
CN111991570A (zh) 一种FAP-α特异性肿瘤诊断SPECT显像剂
Persson et al. First 18F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts
CN118146170A (zh) 用于前列腺癌的腔内放射疗法的前列腺特异性膜抗原靶向的高亲和力剂
CN104379585A (zh) 18f-标记的叶酸/抗叶酸剂类似物
Zhou et al. Synthesis and preclinical evaluation of novel 18F-labeled fibroblast activation protein tracers for positron emission tomography imaging of cancer-associated fibroblasts
Chen et al. Synthesis, preclinical evaluation, and first-in-human PET study of [68Ga]-labeled biphenyl-containing PSMA tracers
JP2023554079A (ja) リガンド及びそれらの使用
Kertész et al. In vivo imaging of experimental melanoma tumors using the novel radiotracer 68Ga-NODAGA-procainamide (PCA)
Chaudhary et al. Design, development and bio-evaluation of a novel radio-ligand 99mTc-THQ-DTPA as a sigma 2 receptor specific breast tumor imaging agent
Shi et al. [68Ga] Ga-HBED-CC-DiAsp: A new renal function imaging agent
US10821194B2 (en) Labelled carboxylic acids and their uses in molecular imaging
Liu et al. Synthesis of novel DOTA-/AAZTA-based bifunctional chelators: Solution thermodynamics, peptidomimetic conjugation, and radiopharmaceutical evaluation
CN120129539A (zh) 放射性核素组合物及其用于检测肿瘤细胞的方法
CN117430537B (zh) 用于诊断或治疗表达前列腺特异性膜抗原肿瘤的新型核素标记巯基衍生物及其应用
US20250339568A1 (en) Precursor and radiotracer for neuroendocrine theranostics
Feng et al. Development of a novel 99mTc-labeled folate derivative containing phenyl isonitrile to target folate receptor with reduced renal uptake
Jiang et al. Evaluation of [18F] FDG/[18F] FLT/[18F] FMISO-based micro-positron emission tomography in detection of liver metastasis in human colorectal cancer
Feng et al. Development of Novel 18F-labelled FAP-Targeting Tracers with Improved Pharmacokinetics: From Preclinical Optimization to Clinical Translation
KR102714797B1 (ko) 황화수소 검출용 이중-방식 프로브 및 이의 용도
WO2020045638A1 (fr) Composé dérivé d'imidazothiadiazole radioactif
CN116375709B (zh) 一种叶酸受体靶向药物、金属络合物及其制备方法与用途
JP2026513316A (ja) 環状ポリペプチド系化合物、及びその使用
CN114149489A (zh) 一种靶向tigit的放射性标记化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination